Kantarjian HM - Search Results

1

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.

DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, de Botton S, Zeidan AM, Fathi AT, Kantarjian HM, Bennett JM, Frattini MG, Martin-Regueira P, Lersch F, Gong J, Hasan M, Vyas P, Döhner H. DiNardo CD, et al. Among authors: kantarjian hm. Lancet Oncol. 2021 Nov;22(11):1597-1608. doi: 10.1016/S1470-2045(21)00494-0. Epub 2021 Oct 18. Lancet Oncol. 2021. PMID: 34672961 Clinical Trial.

2

Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.

Estey E, Thall PF, Kantarjian H, O'Brien S, Koller CA, Beran M, Gutterman J, Deisseroth A, Keating M. Estey E, et al. Blood. 1992 May 1;79(9):2246-55. Blood. 1992. PMID: 1571541 Free article.

3

Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.

Keating MJ, Kantarjian H, O'Brien S, Koller C, Talpaz M, Schachner J, Childs CC, Freireich EJ, McCredie KB. Keating MJ, et al. J Clin Oncol. 1991 Jan;9(1):44-9. doi: 10.1200/JCO.1991.9.1.44. J Clin Oncol. 1991. PMID: 1702145 Clinical Trial.

4

Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia.

O'Brien S, Kantarjian H, Estey E, Koller C, Beran M, McCredie K, Keating M. O'Brien S, et al. Cancer. 1991 Aug 15;68(4):691-4. doi: 10.1002/1097-0142(19910815)68:4<691::aid-cncr2820680404>3.0.co;2-z. Cancer. 1991. PMID: 1855168

5

Response to salvage therapy and survival after relapse in acute myelogenous leukemia.

Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, Beran M, McCredie KB, Freireich EJ. Keating MJ, et al. J Clin Oncol. 1989 Aug;7(8):1071-80. doi: 10.1200/JCO.1989.7.8.1071. J Clin Oncol. 1989. PMID: 2666590

6

Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.

Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, et al. Estey E, et al. J Clin Oncol. 1994 Apr;12(4):671-8. doi: 10.1200/JCO.1994.12.4.671. J Clin Oncol. 1994. PMID: 7512125 Clinical Trial.

7

Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia.

Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Keating MJ. Robertson LE, et al. Leukemia. 1995 Jun;9(6):943-5. Leukemia. 1995. PMID: 7596181 Clinical Trial.

8

Quesnel B, Kantarjian H, Bjergaard JP, Brault P, Estey E, Lai JL, Tilly H, Stoppa AM, Archimbaud E, Harousseau JL, et al. Quesnel B, et al. J Clin Oncol. 1993 Dec;11(12):2370-9. doi: 10.1200/JCO.1993.11.12.2370. J Clin Oncol. 1993. PMID: 8246025 Review.

9

Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.

Estey EH, Kantarjian H, Keating M. Estey EH, et al. Semin Oncol. 1993 Dec;20(6 Suppl 8):1-5. Semin Oncol. 1993. PMID: 8290966 Clinical Trial.

10

Richter's syndrome: a report on 39 patients.

Robertson LE, Pugh W, O'Brien S, Kantarjian H, Hirsch-Ginsberg C, Cork A, McLaughlin P, Cabanillas F, Keating MJ. Robertson LE, et al. J Clin Oncol. 1993 Oct;11(10):1985-9. doi: 10.1200/JCO.1993.11.10.1985. J Clin Oncol. 1993. PMID: 8410123

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,034 results

Search Page